These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 33066143)

  • 1. Cdc-Like Kinases (CLKs): Biology, Chemical Probes, and Therapeutic Potential.
    Martín Moyano P; Němec V; Paruch K
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models.
    Tam BY; Chiu K; Chung H; Bossard C; Nguyen JD; Creger E; Eastman BW; Mak CC; Ibanez M; Ghias A; Cahiwat J; Do L; Cho S; Nguyen J; Deshmukh V; Stewart J; Chen CW; Barroga C; Dellamary L; Kc SK; Phalen TJ; Hood J; Cha S; Yazici Y
    Cancer Lett; 2020 Mar; 473():186-197. PubMed ID: 31560935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic apoptotic effects in cancer cells by the combination of CLK and Bcl-2 family inhibitors.
    Murai A; Ebara S; Sasaki S; Ohashi T; Miyazaki T; Nomura T; Araki S
    PLoS One; 2020; 15(10):e0240718. PubMed ID: 33064779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing.
    Araki S; Dairiki R; Nakayama Y; Murai A; Miyashita R; Iwatani M; Nomura T; Nakanishi O
    PLoS One; 2015; 10(1):e0116929. PubMed ID: 25581376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Cdc2-like Kinase 2 Inhibitors: Achievements and Future Directions.
    Qin Z; Qin L; Feng X; Li Z; Bian J
    J Med Chem; 2021 Sep; 64(18):13191-13211. PubMed ID: 34519506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benzobisthiazoles Represent a Novel Scaffold for Kinase Inhibitors of CLK Family Members.
    Prak K; Kriston-Vizi J; Chan AW; Luft C; Costa JR; Pengo N; Ketteler R
    Biochemistry; 2016 Jan; 55(3):608-17. PubMed ID: 26701387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor.
    Funnell T; Tasaki S; Oloumi A; Araki S; Kong E; Yap D; Nakayama Y; Hughes CS; Cheng SG; Tozaki H; Iwatani M; Sasaki S; Ohashi T; Miyazaki T; Morishita N; Morishita D; Ogasawara-Shimizu M; Ohori M; Nakao S; Karashima M; Sano M; Murai A; Nomura T; Uchiyama N; Kawamoto T; Hara R; Nakanishi O; Shumansky K; Rosner J; Wan A; McKinney S; Morin GB; Nakanishi A; Shah S; Toyoshiba H; Aparicio S
    Nat Commun; 2017 Feb; 8(1):7. PubMed ID: 28232751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of DB18, a potent inhibitor of CLK kinases with a high selectivity against DYRK1A kinase.
    Brahmaiah D; Kanaka Durga Bhavani A; Aparna P; Sampath Kumar N; Solhi H; Le Guevel R; Baratte B; Ruchaud S; Bach S; Singh Jadav S; Raji Reddy C; Roisnel T; Mosset P; Levoin N; Grée R
    Bioorg Med Chem; 2021 Feb; 31():115962. PubMed ID: 33422908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease.
    Jain P; Karthikeyan C; Moorthy NS; Waiker DK; Jain AK; Trivedi P
    Curr Drug Targets; 2014 May; 15(5):539-50. PubMed ID: 24568585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the SR protein-phosphorylating CLK kinases of Plasmodium falciparum impairs blood stage replication and malaria transmission.
    Kern S; Agarwal S; Huber K; Gehring AP; Strödke B; Wirth CC; Brügl T; Abodo LO; Dandekar T; Doerig C; Fischer R; Tobin AB; Alam MM; Bracher F; Pradel G
    PLoS One; 2014; 9(9):e105732. PubMed ID: 25188378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of Clk family kinase and SRp75 modulates alternative splicing of Adenovirus E1A.
    Yomoda J; Muraki M; Kataoka N; Hosoya T; Suzuki M; Hagiwara M; Kimura H
    Genes Cells; 2008 Mar; 13(3):233-44. PubMed ID: 18298798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marine-Derived 2-Aminoimidazolone Alkaloids. Leucettamine B-Related Polyandrocarpamines Inhibit Mammalian and Protozoan DYRK & CLK Kinases.
    Loaëc N; Attanasio E; Villiers B; Durieu E; Tahtouh T; Cam M; Davis RA; Alencar A; Roué M; Bourguet-Kondracki ML; Proksch P; Limanton E; Guiheneuf S; Carreaux F; Bazureau JP; Klautau M; Meijer L
    Mar Drugs; 2017 Oct; 15(10):. PubMed ID: 29039762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temperature does matter-an additional dimension in kinase inhibitor development.
    Strauch M; Heyd F
    FEBS J; 2021 May; 288(10):3148-3153. PubMed ID: 32946682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small Molecule Inhibitors of DYRK1A Identified by Computational and Experimental Approaches.
    Yoon HR; Balupuri A; Choi KE; Kang NS
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability.
    Iwai K; Yaguchi M; Nishimura K; Yamamoto Y; Tamura T; Nakata D; Dairiki R; Kawakita Y; Mizojiri R; Ito Y; Asano M; Maezaki H; Nakayama Y; Kaishima M; Hayashi K; Teratani M; Miyakawa S; Iwatani M; Miyamoto M; Klein MG; Lane W; Snell G; Tjhen R; He X; Pulukuri S; Nomura T
    EMBO Mol Med; 2018 Jun; 10(6):. PubMed ID: 29769258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesis.
    Kettle JG; Ballard P; Bardelle C; Cockerill M; Colclough N; Critchlow SE; Debreczeni J; Fairley G; Fillery S; Graham MA; Goodwin L; Guichard S; Hudson K; Ward RA; Whittaker D
    J Med Chem; 2015 Mar; 58(6):2834-44. PubMed ID: 25738750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases.
    Schmidt M; Rohe A; Platzer C; Najjar A; Erdmann F; Sippl W
    Molecules; 2017 Nov; 22(12):. PubMed ID: 29168755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Selective Clk1 and -4 Inhibitors for Cellular Depletion of Cancer-Relevant Proteins.
    ElHady AK; Abdel-Halim M; Abadi AH; Engel M
    J Med Chem; 2017 Jul; 60(13):5377-5391. PubMed ID: 28561591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of CLK1 Inhibitors by a Fragment-linking Based Virtual Screening.
    Walter A; Chaikuad A; Loaëc N; Preu L; Knapp S; Meijer L; Kunick C; Koch O
    Mol Inform; 2017 Apr; 36(4):. PubMed ID: 28000414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A.
    Falke H; Chaikuad A; Becker A; Loaëc N; Lozach O; Abu Jhaisha S; Becker W; Jones PG; Preu L; Baumann K; Knapp S; Meijer L; Kunick C
    J Med Chem; 2015 Apr; 58(7):3131-43. PubMed ID: 25730262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.